Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond

doi:10.3748/wjg.v25.i7.789

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 25, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (14011)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-8) series.

Item

Count

PDF

1545

WORD

346

HTML

9698

Figures (1-5)

274

Tables (1-8)

237

Sum=12100

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

993

Download

918

Sum=1911

Feb 21, 2019 (publication date) through Apr 19, 2024

Times Cited of This Article

Times Cited (117)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Feb 21, 2019; 25(7): 789-807
Published online Feb 21, 2019. doi: 10.3748/wjg.v25.i7.789

Table 3 Results of the REFLECT trial[34]

	Lenvatinib (n = 478)	Sorafenib (n = 476)	HR, P-value
OS (M, 95% CI)	13.6 (12.1-14.9)	12.3 (10.4-13.9)	HR 0.92 (0.79-1.06)
PFS (M, 95% CI)	7.3 (5.6-7.5)	3.6 (3.6-3.7)	HR 0.64 (0.55-0.75) P < 0.0001
TTP (M, 95% CI)	7.4 (7.2-9.1)	3.7 (3.6-3.9)	HR 0.60 (0.51-0.71) P < 0.0001
Objective response (independent review, mRECIST)
CR	10 (2%)	4 (1%)
PR	184 (38%)	55 (12%)
SD	159 (33%)	219 (46%)
PD	79 (17%)	152 (32%)
ORR	194 (40.6%)	59 (12.4%)	P < 0.0001
DCR	353 (73.8%)	278 (58.4%)	P < 0.0001

OS: Overall survival; PFS: Progression-free survival; TTP: Time to progression; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; ORR: Objective response rate; DCR: Disease control rate.

Citation: Kudo M. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond. World J Gastroenterol 2019; 25(7): 789-807
URL: https://www.wjgnet.com/1007-9327/full/v25/i7/789.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i7.789